Lupin 2023

Former Merck executive joins The New England Consulting Group

Print Friendly, PDF & Email

WESTPORT, Conn. – The New England Consulting Group (NECG) welcomes Theodora Bibila as a Principal and Advisor to its healthcare and vaccine practices. Dora brings over 25 years of demonstrated success in the pharmaceutical and biotech industries leading global vaccine launches, treatments and commercialization for major players, including Merck and Biogen.

Most recently, Dora was the Vice President of Global Product Development and Commercialization at Biogen where she led cross-functional teams progressing the Alzheimer’s disease product portfolio, and the collaboration with Eisai.

“I am honored to be joining the NECG network of talented and experienced professionals,” said Dora. “And I’m looking forward to contributing as part of the healthcare and vaccine practice teams.”

Prior to Biogen, Dora held numerous senior executive positions at Merck guiding international business and marketing for vaccines such as Recombivax, RotaTeq and Gardasil and global access strategies for GAVI. She expanded best-in-class key accounts around the world as a senior marketing forerunner and earned the role of Associate Vice President General Manager of Merck’s Biosimilar business successfully leading the Samsung Bioepis partnership and creating a broad portfolio of immunology, oncology and diabetes biosimilars focusing on policy, access, pricing and physician/patient support programs.

“Dora’s breadth of experience and success creating emerging and revitalizing aging products/brands will prove invaluable to all of our clients and any professional marketer,” said Gary Stibel, Founder & CEO of NECG. “I’m thrilled to welcome Dora to our healthcare and vaccine practice teams.” 

Comments are closed.